Advances in clinical chemistry. Volume 66 / edited by Gregory S. Makowski.

Format:

Book

Contributor:

Makowski, Gregory S., editor.

Series:

Advances in Clinical Chemistry ; Volume 66

Language:

English

Subjects (All):

Biochemistry.

Clinical chemistry.

Physical Description:

1 online resource (314 p.)

Edition:

First edition.

Place of Publication:

Waltham, Massachusetts : Elsevier, 2014.

Language Note:

English

Summary:

Volume 66 in the internationally acclaimed <i>Advances in Clinical Chemistry</i> contains chapters authored by world renowned clinical laboratory scientists, physicians and research scientists. The serial provides the latest and most up-to-date technologies related to the field of Clinical Chemistry and is the benchmark for novel analytical approaches in the clinical laboratory. <br><br><ul><li>Expertise of international contributors</li><li>Latest cutting-edge technologies</li><li>Comprehensive in scope</li></ul>

Contents:

Front Cover; Advances in Clinical Chemistry ; Copyright; Contents; Contributors; Preface; Chapter One: PSA in Screening for Prostate Cancer: More Good than Harm or More Harm than Good?; 1. Introduction; 2. PSA: A Protease with Multiple Isoforms; 3. PSA as a Screening Test for Prostate Cancer; 4. Evaluation of PSA as a Screening Test for Prostate Cancer; 4.1. Randomized prospective trials; 4.2. Systematic reviews and meta-analysis of screening trials; 5. Potential Harms of Prostate Cancer Screening; 6. Attempts to Increase Benefits and Decrease Harms of PSA Screening

7. Attempts to Improve the Accuracy of PSA in Detecting Prostate Cancer7.1. Percent-free PSA (free/total ratio); 7.2. PCA3; 7.3. ProPSA; 7.4. TMPRSS2-ETS fusion mRNA; 7.5. Other emerging markers; 8. Conclusion; References; Chapter Two: Ovarian Cancer Biomarkers: Current State and Future Implications from High-Throughput Technologies; 1. Introduction; 2. Ovarian Cancer; 2.1. Etiology; 2.2. Pathophysiology; 2.3. Clinical management; 2.3.1. Staging and diagnosis of ovarian cancer; 2.3.2. Pelvic mass dilemma; 3. Tumor Markers; 3.1. Types of tumor markers; 3.2. Tumor marker guidelines

3.3. Biomarker development4. FDA-Approved Biomarkers; 4.1. CA125; 4.2. HE4; 4.3. ROMA; 4.4. OVA1; 5. Other Prominent Biomarkers; 5.1. PLCO markers; 5.1.1. Mesothelin; 5.1.2. Interleukin-6 and interleukin-8; 5.1.3. B7-H4; 5.1.4. Osteopontin; 5.1.5. Kallikreins; 5.2. Other markers; 5.2.1. Vascular endothelial growth factor; 5.2.2. Prostasin; 6. Emerging Biomarker Research; 6.1. MicroRNAs; 6.1.1. Diagnosis; 6.1.2. Prognosis; 6.1.3. Therapeutic resistance; 6.2. Targeted proteomics; 6.2.1. Glycomics; 6.2.2. Metabolomics; 6.2.3. Peptidomics; 6.2.4. Autoantibody signatures

6.3. Circulating tumor DNA6.3.1. Pre-NGS Era; 6.3.2. NGS platforms and beyond; 7. Conclusion; References; Chapter Three: Procollagen Assays in Cancer; 1. Introduction; 2. Procollagen Assays: Principles and Methods; 2.1. Type I procollagen; 2.2. Type III procollagen; 3. Fibroproliferation in Healthy Tissues and Cancer; 4. Bone Turnover in Health and Malignant Disease; 5. Effects of Malignant Bone Lesions on Procollagen Propeptides; 5.1. Prostate cancer; 5.2. Breast cancer; 5.3. Other malignancies; 6. Clinical Use of Procollagen Propeptides; 7. Conclusion; References

Chapter Four: Metabolomics in Dyslipidemia1. Introduction; 2. Metabolomics; 3. Data Collection; 4. Data Analysis; 5. Hyperlipidemia; 6. Metabolomics in Hyperlipidemia; 6.1. Metabolomics in animal research; 6.1.1. Animal pathologic model research; 6.1.2. Antilipemic agent research; 6.2. Metabolomics in clinical research; 7. Conclusion; Acknowledgments; References; Chapter Five: Metabolism in Chronic Fatigue Syndrome; 1. Introduction; 2. Chronic Fatigue Syndrome; 2.1. Definition; 2.2. Diagnosis and symptoms; 2.3. Epidemiology; 2.3.1. History; 2.3.2. Pathogens and immune system

2.3.3. Gastrointestinal microbiota

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

Description based on online resource; title from PDF title page (ebrary, viewed August 27, 2014).

ISBN:

0-12-801612-4